C11517: Novel Synthetic Genomic Reconstruct for HCV TherapeuticsNovelty:
This technology is an optimized synthetic reconstruct of genotype 1a hepatitis C virus (HCV) that is representative of globally-circulating strains of HCV
Value Proposition:
The reconstructed HCV genotype 1a virus is highly functional without adaptive mutations, which allows it to become a representative of circulating strains found in humans. Other advantages include:
• Addresses unmet needs in HCV research and those who are hampered by limitations to arbitrary virus isolates
.
• Data suggest that this virus is highly immunogenic
.
Technical Details:
Johns Hopkins researchers have developed a representative HCV genomic sequence that has been shown to provide a more promising potential than current in vitro HCV isolates. This method can be applied to each of the major genotypes and subtypes of HCV. More specifically, this novel sequence is designed to avoid idiosyncratic changes that reduce fitness and immune recognition. Derivations of sequences from this method will have value in the development of therapeutic agents and vaccines, and in studies of HCV virology, immunology, and cell biology.
Looking for Partners:
To develop & commercialize the technology into a Hepatitis C synthetic vaccine into clinical trials.
Stage of Development:
Commercial use
Data Availability:
Under CDA / NDA
Publications/Associated Cases:
J Virol. 2012 May;86(10):5915-21. Epub 2012 Mar 21
